Manufacturers submit market authorisation application for daridorexant for insomnia to the European Medicines Agency
Evidence from a phase III registration programme found statistically significant and clinically meaningful improvements in sleep duration, patient perceived sleep quantity and quality and improvement in daytime function for this dual orexin receptor agonist.
Source:
PharmaTimes